VEGFA and metastatic colorectal cancer: This may indicate that VEGF expression may not only serve as a prognostic marker, but also that adding anti-VEGF antibody based therapies, i.e., bevacizumab, could have additional therapeutic value in this subgroup of metastatic colorectal cancer patients.